Exact Sciences Secures All Regulatory Approvals for Abbott Merger, Anticipates March 23 Close
EXAS has more than doubled off its 52-week low of $38.812.
Summary
Exact Sciences announced it has received all necessary regulatory approvals for its merger with Abbott Laboratories, with the transaction now expected to close on March 23, 2026.
Key Events · M&A and Partnerships · EXAS
-
Regulatory Approvals Secured
Exact Sciences and Abbott Laboratories have received all required regulatory approvals and clearances for their merger as of March 19, 2026.
-
Merger Closing Imminent
The merger is now anticipated to close on March 23, 2026, subject to the satisfaction or waiver of remaining conditions.
-
Prior Shareholder Approval
Exact Sciences' stockholders previously approved the merger at a special meeting on February 20, 2026.
Analysis · EXAS · Industrial Applications And Services
This 8-K provides a critical update on the previously announced merger with Abbott Laboratories. The confirmation that all regulatory approvals and clearances have been secured significantly de-risks the transaction and makes the anticipated closing on March 23, 2026, highly probable. This positive development removes a major uncertainty for investors regarding the acquisition, which was first disclosed in the company's 10-K filing on February 13, 2026. The successful completion of this merger will fundamentally alter Exact Sciences' corporate structure and strategic direction.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXAS was trading at $104.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.8B. The 52-week trading range was $38.81 to $104.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.